Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 51

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection

Guillaume, Olivier, Butnarasu, Cosmin, Visentin, Sonja, Reimhult, Erik · 2022 · Biofilm

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bioflm.2022.100089

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 130

  1. Hilker, 2015, Interclonal gradient of virulence in the Pseudomonas aeruginosa pangenome from disease and environment, Environ Microbiol, 17, 29, 10.1111/1462-2920.12606 · DOI
  2. Jennings, 2021, Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies, Cell Rep, 34, 10.1016/j.celrep.2021.108782 · DOI · Paper page
  3. Høiby, 2011, Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis, BMC Med, 9, 32, 10.1186/1741-7015-9-32 · DOI · Paper page
  4. Rau, 2010, Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts, Environ Microbiol, 12, 1643, 10.1111/j.1462-2920.2010.02211.x · DOI
  5. Barclay, 1996, Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis, J Antimicrob Chemother, 37, 1155, 10.1093/jac/37.6.1155 · DOI
  6. Fernández, 2010, Adaptive resistance to the “last hope” antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS, Antimicrob Agents Chemother, 54, 3372, 10.1128/AAC.00242-10 · DOI · Paper page
  7. MacLeod, 2000, Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment, J Infect Dis, 181, 1180, 10.1086/315312 · DOI
  8. Hentzer, 2001, Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function, J Bacteriol, 183, 5395, 10.1128/JB.183.18.5395-5401.2001 · DOI · Paper page
  9. Cookson, 2018, New opportunities for managing acute and chronic lung infections, Nat Rev Microbiol, 16, 111, 10.1038/nrmicro.2017.122 · DOI
  10. Mahenthiralingam, 2014, Emerging cystic fibrosis pathogens and the microbiome, Paediatr Respir Rev, 15, 13
  11. Bittar, 2010, Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients, Clin Microbiol Infect, 16, 809, 10.1111/j.1469-0691.2010.03236.x · DOI
  12. Ma, 2022, Regulation of biofilm exopolysaccharide biosynthesis and degradation in Pseudomonas aeruginosa, Annu Rev Microbiol, 76, 10.1146/annurev-micro-041320-111355 · DOI
  13. Hoiby, 2010, Pseudomonas aeruginosa biofilms in cystic fibrosis, Future Microbiol, 5, 1663, 10.2217/fmb.10.125 · DOI · Paper page
  14. Doggett, 1969, Incidence of mucoid Pseudomonas aeruginosa from clinical sources, Appl Microbiol, 18, 936, 10.1128/am.18.5.936-937.1969 · doi:10.1128/am.18.5.936-937.1969
  15. Linker, 1964, A polysaccharide resembling alginic acid from a Pseudomonas micro-organism, Nature, 204, 187, 10.1038/204187a0 · DOI · Paper page
  16. Evans, 1973, Production and characterization of the slime polysaccharide of Pseudomonas aeruginosa, J Bacteriol, 116, 915, 10.1128/jb.116.2.915-924.1973 · DOI · Paper page
  17. May, 1991, Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients, Clin Microbiol Rev, 4, 191, 10.1128/CMR.4.2.191 · DOI · Paper page
  18. Lee, 2005, Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis, J Clin Microbiol, 43, 5247, 10.1128/JCM.43.10.5247-5255.2005 · DOI
  19. Guo, 2020, Structures, properties and application of alginic acid: a review, Int J Biol Macromol, 162, 618, 10.1016/j.ijbiomac.2020.06.180 · DOI · Paper page
  20. Massip-Copiz, 2018, Extracellular pH and lung infections in cystic fibrosis, Eur J Cell Biol, 97, 402, 10.1016/j.ejcb.2018.06.001 · DOI
  21. Ojoo, 2005, Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis, Thorax, 60, 22, 10.1136/thx.2003.017327 · DOI · Paper page
  22. Braccini, 1999, Conformational and configurational features of acidic polysaccharides and their interactions with calcium ions: a molecular modeling investigation, Carbohydr Res, 317, 119, 10.1016/S0008-6215(99)00062-2 · DOI · Paper page
  23. Smith, 2014, Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity, J Cyst Fibros, 13, 289, 10.1016/j.jcf.2013.12.001 · DOI
  24. Lam, 1980, Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis, Infect Immun, 28, 546, 10.1128/iai.28.2.546-556.1980 · DOI · Paper page
  25. Gordon, 1988, Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa, J Antimicrob Chemother, 22, 667, 10.1093/jac/22.5.667 · DOI · Paper page
  26. Nichols, 1988, Inhibition of tobramycin diffusion by binding to alginate, Antimicrob Agents Chemother, 32, 518, 10.1128/AAC.32.4.518 · DOI · Paper page
  27. lannuccelli, 1996, Biodegradable intraoperative system for bone infection treatment. I. The drug/polymer interaction, Int J Pharm, 143, 195, 10.1016/S0378-5173(96)04703-5 · DOI
  28. Heriot, 2019, Interaction of gentamicin sulfate with alginate and consequences on the physico-chemical properties of alginate-containing biofilms, Int J Biol Macromol, 121, 390, 10.1016/j.ijbiomac.2018.10.025 · DOI
  29. Song, 2014, Stiffness of cross-linked poly(dimethylsiloxane) affects bacterial adhesion and antibiotic susceptibility of attached cells, Langmuir, 30, 10354, 10.1021/la502029f · DOI
  30. Chanasit, 2020, Analysis of the alginate O-acetylation machinery in Pseudomonas aeruginosa, Appl Microbiol Biotechnol, 104, 2179, 10.1007/s00253-019-10310-6 · DOI
  31. Mayer, 1999, The role of intermolecular interactions: studies on model systems for bacterial biofilms, Int J Biol Macromol, 26, 3, 10.1016/S0141-8130(99)00057-4 · DOI · Paper page
  32. DiRita, 2001, Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis, Infect Immun, 69, 1895, 10.1128/IAI.69.3.1895-1901.2001 · DOI · Paper page
  33. Ertesvåg, 2015, Alginate-modifying enzymes: biological roles and biotechnological uses, Front Microbiol, 6
  34. Lamppa, 2013, Alginate lyase exhibits catalysis-independent biofilm dispersion and antibiotic synergy, Antimicrob Agents Chemother, 57, 137, 10.1128/AAC.01789-12 · DOI
  35. Skjåk-Bræk, 1989, Effect of acetylation on some solution and gelling properties of alginates, Carbohydr Res, 185, 131, 10.1016/0008-6215(89)84028-5 · DOI
  36. Boucher, 2007, Evidence for airway surface dehydration as the initiating event in CF airway disease, J Intern Med, 261, 5, 10.1111/j.1365-2796.2006.01744.x · DOI · Paper page
  37. Schnider-Keel, 2001, The sigma factor AlgU (AlgT) controls exopolysaccharide production and tolerance towards desiccation and osmotic stress in the biocontrol agent Pseudomonas fluorescens CHA0, Appl Environ Microbiol, 67, 5683, 10.1128/AEM.67.12.5683-5693.2001 · DOI
  38. DeVault, 1990, Pulmonary dehydration and infection in cystic fibrosis: evidence that ethanol activates alginate gene expression and induction of mucoidy in Pseudomonas aeruginosa, Mol Microbiol, 4, 737, 10.1111/j.1365-2958.1990.tb00644.x · DOI
  39. Tashiro, 2014, Low concentrations of ethanol stimulate biofilm and pellicle formation in Pseudomonas aeruginosa, Biosci Biotechnol Biochem, 78, 178, 10.1080/09168451.2014.877828 · doi:10.1080/09168451.2014.877828
  40. Ibáñez de Aldecoa, 2017, Mechanisms and regulation of extracellular DNA release and its biological roles in microbial communities, Front Microbiol, 8, 10.3389/fmicb.2017.01390 · DOI · Paper page
  41. Potter, 1969, Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy, Am Rev Respir Dis, 99, 909
  42. Shah, 1996, In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, Thorax, 51, 119, 10.1136/thx.51.2.119 · DOI
  43. Picot, 1978, Pus, deoxyribonucleic acid, and sputum viscosity, Thorax, 33, 235, 10.1136/thx.33.2.235 · doi:10.1136/thx.33.2.235
  44. Mulcahy, 2008, Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms, PLoS Pathog, 4, 10.1371/journal.ppat.1000213 · DOI · Paper page
  45. Egli, 2002, DNA-cation interactions: quo vadis?, Chem Biol, 9, 277, 10.1016/S1074-5521(02)00116-3 · DOI · Paper page
  46. Dobi, 1998, Submillimolar levels of calcium regulates DNA structure at the dinucleotide repeat (TG/AC)n, Proc Natl Acad Sci U S A, 95, 5981, 10.1073/pnas.95.11.5981 · DOI
  47. Powell, 2018, Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides, NPJ Biofilms Microbiomes, 4, 13, 10.1038/s41522-018-0056-3 · DOI · Paper page
  48. Alhede, 2020, The origin of extracellular DNA in bacterial biofilm infections in vivo, Pathog Dis, 78, 10.1093/femspd/ftaa018 · DOI
  49. Chiang, 2013, Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms, Antimicrob Agents Chemother, 57, 2352, 10.1128/AAC.00001-13 · DOI · Paper page
  50. Allesen-Holm, 2006, A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms, Mol Microbiol, 59, 1114, 10.1111/j.1365-2958.2005.05008.x · DOI · Paper page
  51. Lethem, 1990, The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum, Eur Respir J, 3, 19, 10.1183/09031936.93.03010019 · DOI · Paper page
  52. Martínez-Alemán, 2017, Understanding the entanglement: neutrophil extracellular traps (NETs) in cystic fibrosis, Front Cell Infect Microbiol, 7, 10.3389/fcimb.2017.00104 · DOI
  53. Wang, 2015, The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in Pseudomonas aeruginosa, Environ Microbiol Rep, 7, 330, 10.1111/1758-2229.12252 · DOI · Paper page
  54. Seviour, 2021, The biofilm matrix scaffold of Pseudomonas aeruginosa contains G-quadruplex extracellular DNA structures, Npj Biofilms Microbi, 7, 10.1038/s41522-021-00197-5 · DOI
  55. Dell'Anno, 2005, Extracellular DNA plays a key role in deep-sea ecosystem functioning, Science, 309, 10.1126/science.1117475 · DOI · Paper page
  56. Mulcahy, 2010, Pseudomonas aeruginosa produces an extracellular deoxyribonuclease that is required for utilization of DNA as a nutrient source, Environ Microbiol, 12, 1621, 10.1111/j.1462-2920.2010.02208.x · DOI · Paper page
  57. Prudhomme, 2006, Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae, Science, 313, 89, 10.1126/science.1127912 · DOI · Paper page
  58. Rajendran, 2013, Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms, Eukaryot Cell, 12, 420, 10.1128/EC.00287-12 · DOI · Paper page
  59. Freschi, 2018, The Pseudomonas aeruginosa pan-genome provides new insights on its population structure, horizontal gene transfer, and pathogenicity, Genome Biology and Evolution, 11, 109, 10.1093/gbe/evy259 · DOI · Paper page
  60. Qiu, 2009, Role of horizontal gene transfer in the evolution of Pseudomonas aeruginosa virulence, Genome Dyn, 6, 126, 10.1159/000235767 · DOI
  61. Wilton, 2016, Extracellular DNA acidifies biofilms and induces aminoglycoside resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 60, 544, 10.1128/AAC.01650-15 · DOI · Paper page
  62. Friedman, 2004, Genes involved in matrix formation in Pseudomonas aeruginosa PA14 biofilms, Mol Microbiol, 51, 675, 10.1046/j.1365-2958.2003.03877.x · DOI · Paper page
  63. Jennings, 2015, Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix, Proc Natl Acad Sci USA, 112, 11353, 10.1073/pnas.1503058112 · DOI · Paper page
  64. Häussler, 2009, New perspectives at the heart of surface-associated microbial communities, J Bacteriol, 192, 2941, 10.1128/JB.00332-10 · DOI
  65. Colvin, 2011, The pel polysaccharide can serve a structural and protective role in the biofilm matrix of Pseudomonas aeruginosa, PLoS Pathog, 7, 10.1371/journal.ppat.1001264 · DOI · Paper page
  66. Madsen, 2015, Facultative control of matrix production optimizes competitive fitness in Pseudomonas aeruginosa PA14 biofilm models, Appl Environ Microbiol, 81, 8414, 10.1128/AEM.02628-15 · DOI
  67. Yoon, 2002, Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis, Dev Cell, 3, 593, 10.1016/S1534-5807(02)00295-2 · DOI · Paper page
  68. Montgomery, 2017, Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies, Eur Respir J, 49, 10.1183/13993003.00903-2016 · DOI
  69. Borriello, 2004, Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms, Antimicrob Agents Chemother, 48, 2659, 10.1128/AAC.48.7.2659-2664.2004 · DOI · Paper page
  70. Khan, 2010, Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide, Int Microbiol, 13, 207
  71. Friedman, 2004, Two genetic loci produce distinct carbohydrate-rich structural components of the Pseudomonas aeruginosa biofilm matrix, J Bacteriol, 186, 4457, 10.1128/JB.186.14.4457-4465.2004 · DOI · Paper page
  72. Ma, 2007, Pseudomonas aeruginosa Psl is a galactose- and mannose-rich exopolysaccharide, J Bacteriol, 189, 8353, 10.1128/JB.00620-07 · DOI · Paper page
  73. Byrd, 2009, Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production, Mol Microbiol, 73, 622, 10.1111/j.1365-2958.2009.06795.x · DOI · Paper page
  74. Ma, 2012, Synthesis of multiple Pseudomonas aeruginosa biofilm matrix exopolysaccharides is post-transcriptionally regulated, Environ Microbiol, 14, 1995, 10.1111/j.1462-2920.2012.02753.x · DOI
  75. Colvin, 2012, The Pel and Psl polysaccharides provide Pseudomonas aeruginosa structural redundancy within the biofilm matrix, Environ Microbiol, 14, 1913, 10.1111/j.1462-2920.2011.02657.x · DOI · Paper page
  76. Kovach, 2017, Evolutionary adaptations of biofilms infecting cystic fibrosis lungs promote mechanical toughness by adjusting polysaccharide production, Npj Biofilms Microbi, 3, 1, 10.1038/s41522-016-0007-9 · DOI
  77. Ma, 2009, Assembly and development of the Pseudomonas aeruginosa biofilm matrix, PLoS Pathog, 5, 10.1371/journal.ppat.1000354 · DOI · Paper page
  78. Mishra, 2012, Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization, Cell Microbiol, 14, 95, 10.1111/j.1462-5822.2011.01704.x · DOI · Paper page
  79. Jones, 2017, Psl produced by mucoid Pseudomonas aeruginosa contributes to the establishment of biofilms and immune evasion, mBio, 8, 10.1128/mBio.00864-17 · DOI
  80. Borlee, 2010, Pseudomonas aeruginosa uses a cyclic-di-GMP-regulated adhesin to reinforce the biofilm extracellular matrix, Mol Microbiol, 75, 827, 10.1111/j.1365-2958.2009.06991.x · DOI · Paper page
  81. Reichhardt, 2018, CdrA interactions within the Pseudomonas aeruginosa biofilm matrix safeguard it from proteolysis and promote cellular packing, mBio, 9, 10.1128/mBio.01376-18 · DOI
  82. Passos da Silva, 2019, The Pseudomonas aeruginosa lectin LecB binds to the exopolysaccharide Psl and stabilizes the biofilm matrix, Nat Commun, 10, 2183, 10.1038/s41467-019-10201-4 · DOI · Paper page
  83. Geddes-McAlister, 2019, Tasked with a challenging objective: why do neutrophils fail to battle Pseudomonas aeruginosa biofilms, Pathogens, 8, 283, 10.3390/pathogens8040283 · DOI
  84. Govan, 1996, Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia, Microbiol Rev, 60, 539, 10.1128/mr.60.3.539-574.1996 · doi:10.1128/mr.60.3.539-574.1996 · Paper page
  85. Billings, 2013, The extracellular matrix component psl provides fast-acting antibiotic defense in Pseudomonas aeruginosa biofilms, PLoS Pathog, 9, 10.1371/journal.ppat.1003526 · DOI · Paper page
  86. Hansson, 2019, Mucus and mucins in diseases of the intestinal and respiratory tracts, J Intern Med, 285, 479, 10.1111/joim.12910 · DOI · Paper page
  87. Bromberg, 1999, Aggregation phenomena in aqueous solutions of hydrophobically modified polyelectrolytes, A Probe Solubilization Study, Macromolecules, 32, 3649, 10.1021/ma981946k · DOI
  88. Raynal, 2002, Concentrated solutions of salivary MUC5B mucin do not replicate the gel-forming properties of saliva, Biochem J, 362 Pt 2, 289, 10.1042/bj3620289 · DOI
  89. Schipper, 2007, Saliva as research material: biochemical, physicochemical and practical aspects, Arch Oral Biol, 52, 1114, 10.1016/j.archoralbio.2007.06.009 · DOI · Paper page
  90. Petrou, 2018, Mucins as multifunctional building blocks of biomaterials, Biomater Sci, 6, 2282, 10.1039/C8BM00471D · DOI · Paper page
  91. Mitri, 2020, Novel anti-inflammatory approaches for cystic fibrosis lung disease: identification of molecular targets and design of innovative therapies, Front Pharmacol, 11, 1096, 10.3389/fphar.2020.01096 · DOI
  92. Song, 2003, Interleukin-1β and tumor necrosis factor-α induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells, J Biol Chem, 278, 23243, 10.1074/jbc.M300096200 · DOI · Paper page
  93. Yeung, 2012, Mucin promotes rapid surface motility in Pseudomonas aeruginosa, mBio, 3, 10.1128/mBio.00073-12 · DOI
  94. Landry, 2006, Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance, Mol Microbiol, 59, 142, 10.1111/j.1365-2958.2005.04941.x · DOI · Paper page
  95. Haley, 2012, Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium, BMC Microbiol, 12, 10.1186/1471-2180-12-181 · DOI
  96. Co, 2018, Mucins trigger dispersal of Pseudomonas aeruginosa biofilms, Npj Biofilms Microbi, 4, 23, 10.1038/s41522-018-0067-0 · DOI · Paper page
  97. Van den Bossche, 2021, The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects, Eur Respir Rev, 30, 10.1183/16000617.0055-2021 · DOI
  98. Baos, 2012, Distribution of sialic acids on mucins and gels: a defense mechanism, Biophys J, 102, 176, 10.1016/j.bpj.2011.08.058 · DOI
  99. Kim, 2020, N-glycan modifications with negative charge in a natural polymer mucin from bovine submaxillary glands, and their structural role, Polymers (Basel), 13, 10.3390/polym13010103 · DOI
  100. Huang, 2015, Mucin binding reduces colistin antimicrobial activity, Antimicrob Agents Chemother, 59, 5925, 10.1128/AAC.00808-15 · DOI
  101. Samad, 2019, Mucus and mucin environments reduce the efficacy of polymyxin and fluoroquinolone antibiotics against Pseudomonas aeruginosa, ACS Biomater Sci Eng, 5, 1189, 10.1021/acsbiomaterials.8b01054 · DOI
  102. Grainger, 2006, Culture of calu-3 cells at the air interface provides a representative model of the airway epithelial barrier, Pharmaceut Res, 23, 1482, 10.1007/s11095-006-0255-0 · DOI · Paper page
  103. Lock, 2018, Mucus models to evaluate the diffusion of drugs and particles, Adv Drug Deliv Rev, 124, 34, 10.1016/j.addr.2017.11.001 · DOI · Paper page
  104. Pacheco, 2019, Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery, J Mater Chem B, 7, 4940, 10.1039/C9TB00957D · DOI
  105. Bhat, 1996, Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology, J Pharmacol Sci, 85, 624, 10.1021/js950381s · DOI
  106. Butnarasu, 2022, Cystic fibrosis mucus model to design more efficient drug therapies, Mol Pharm, 19, 520, 10.1021/acs.molpharmaceut.1c00644 · DOI
  107. Petri, 2003, Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo, Drug Metab Dispos, 31, 805, 10.1124/dmd.31.6.805 · DOI · Paper page
  108. Bhattacharjee, 2017, Nanoparticle passage through porcine jejunal mucus: microfluidics and rheology, Nanomed Nanotechnol Biol Med, 13, 863, 10.1016/j.nano.2016.11.017 · DOI
  109. Boegh, 2014, Property profiling of biosimilar mucus in a novel mucus-containing in vitro model for assessment of intestinal drug absorption, Eur J Pharm Biopharm, 87, 227, 10.1016/j.ejpb.2014.01.001 · DOI
  110. Falavigna, 2018, Mucus-PVPA (mucus Phospholipid Vesicle-based Permeation Assay): an artificial permeability tool for drug screening and formulation development, Int J Pharm, 537, 213, 10.1016/j.ijpharm.2017.12.038 · DOI
  111. Wang, 2021, Mucin glycans signal through the sensor kinase RetS to inhibit virulence-associated traits in Pseudomonas aeruginosa, Curr Biol, 31, 90, 10.1016/j.cub.2020.09.088 · DOI
  112. Morrison, 2019, Mucus, mucins, and cystic fibrosis, Pediatr Pulmonol, 54, S84
  113. Wheeler, 2019, Mucin glycans attenuate the virulence of Pseudomonas aeruginosa in infection, Nat Microbiol, 4, 2146, 10.1038/s41564-019-0581-8 · DOI · Paper page
  114. Hoffman, 2020, Host mucin is exploited by Pseudomonas aeruginosa to provide monosaccharides required for a successful infection, mBio, 11, 10.1128/mBio.00060-20 · DOI
  115. Tang, 2016, Acidic pH increases airway surface liquid viscosity in cystic fibrosis, J Clin Invest, 126, 879, 10.1172/JCI83922 · DOI · Paper page
  116. Smith, 2013, Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis, Eur Respir J, 42, 1723, 10.1183/09031936.00124012 · DOI
  117. Tyrrell, 2016, Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies, Microbiology, 162, 191, 10.1099/mic.0.000220 · DOI · Paper page
  118. Dieppois, 2012, The transcriptional regulator CzcR modulates antibiotic resistance and quorum sensing in Pseudomonas aeruginosa, PLoS One, 7, 10.1371/journal.pone.0038148 · DOI
  119. Aspedon, 2006, Microarray analysis of the osmotic stress response in Pseudomonas aeruginosa, J Bacteriol, 188, 2721, 10.1128/JB.188.7.2721-2725.2006 · DOI
  120. Price-Whelan, 2006, Rethinking 'secondary' metabolism: physiological roles for phenazine antibiotics, Nat Chem Biol, 2, 71, 10.1038/nchembio764 · DOI · Paper page
  121. Mavrodi, 2001, Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from Pseudomonas aeruginosa PAO1, J Bacteriol, 183, 6454, 10.1128/JB.183.21.6454-6465.2001 · DOI · Paper page
  122. Lauredo, 1998, Mechanism of pyocyanin- and 1-hydroxyphenazine-induced lung neutrophilia in sheep airways, J Appl Physiol, 85, 2298, 10.1152/jappl.1998.85.6.2298 · DOI
  123. Lau, 2004, Pseudomonas aeruginosa pyocyanin is critical for lung infection in mice, Infect Immun, 72, 4275, 10.1128/IAI.72.7.4275-4278.2004 · DOI · Paper page
  124. Das, 2015, Phenazine virulence factor binding to extracellular DNA is important for Pseudomonas aeruginosa biofilm formation, Sci Rep-Uk, 5, 8398, 10.1038/srep08398 · DOI · Paper page
  125. Mah, 2003, A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance, Nature, 426, 306, 10.1038/nature02122 · DOI · Paper page
  126. Sadovskaya, 2010, High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated β-(1→3)-glucans, which bind aminoglycosides, Glycobiology, 20, 895, 10.1093/glycob/cwq047 · DOI
  127. Scoffone, 2019, Quorum sensing as antivirulence target in cystic fibrosis pathogens, Int J Mol Sci, 20, 1838, 10.3390/ijms20081838 · DOI
  128. Balasubramanian, 2012, A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence, Nucleic Acids Res, 41, 1, 10.1093/nar/gks1039 · DOI · Paper page
  129. Briaud, 2020, Impact of coexistence phenotype between Staphylococcus aureus and Pseudomonas aeruginosa isolates on clinical outcomes among cystic fibrosis patients, Front Cell Infect Microbiol, 10, 266, 10.3389/fcimb.2020.00266 · DOI
  130. Camus, 2021, How bacterial adaptation to cystic fibrosis environment shapes interactions between Pseudomonas aeruginosa and Staphylococcus aureus, Front Microbiol, 12, 10.3389/fmicb.2021.617784 · DOI

Cited by

See all 51

Metadata

Authors
Guillaume, O., Butnarasu, C., Visentin, S., & Reimhult, E.
Venue
Biofilm
Publisher
Elsevier BV
Published
2022-12
Volume
4
Pages
100089
ISSN
2590-2075
Cited by
51
References
5
Language
en
Licence
Funders
  • FWF
  • Technische Universität Wien

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection. https://app.cochat.ai/papers/10.1016/j.bioflm.2022.100089
The paper
Guillaume, O., Butnarasu, C., Visentin, S., & Reimhult, E. (2022). Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection. Biofilm. https://doi.org/10.1016/j.bioflm.2022.100089

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.